Comments
Novartis third-quarter sales miss expectations
25.10.2012. | ZURICH (Reuters) - Swiss drugmaker Novartis posted worse-than-expected third quarter sales on Thursday, dragged down by the loss of a U.S. patent on its top-selling blood pressure drug Diovan and tough comparisons at its Sandoz unit....
